


MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p style="text-align: center;">Licensee</p> <p>1. Johnson County Memorial Hospital</p> <p>2. P.O. Box 549 1125 Jefferson St. Franklin, IN 46131</p>	<p>In accordance with letter dated August 10, 2022,</p> <p>3. License No.: 13-14817-01 is amended in its entirety to read as follows:</p>	<p>4. Expiration Date: December 31, 2023</p>
		<p>5. Docket No.: 030-08553 Reference No.:</p>
<p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material permitted by 10 CFR 35.100</p> <p>B. Any byproduct material permitted by 10 CFR 35.200</p> <p>C. Any byproduct material permitted by 10 CFR 35.300</p> <p>D. Any byproduct material permitted by 10 CFR 31.11</p>	<p>7. Chemical and/or physical form</p> <p>A. Any</p> <p>B. Any</p> <p>C. Any</p> <p>D. Prepackaged Kits</p>	<p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As Needed</p> <p>B. As Needed</p> <p>C. 350 millicuries total</p> <p>D. 10 millicuries total</p>
		<p>9. Authorized use</p> <p>A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.</p> <p>B. For use in imaging and localization studies permitted by 10 CFR 35.200.</p> <p>C. For any use permitted by 10 CFR 35.300.</p> <p>D. For use in in-vitro studies.</p>



**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 13-14817-01

Docket or Reference No.:
030-08553

Amendment No. 34

CONDITIONS

10. A. Licensed material shall be used or stored at the licensee's facilities located at 1125 W Jefferson St., Franklin, Indiana 46131.
B. Licensed material listed in Subitem No. 6.B. shall be used at the licensee's facilities located at 1155 W Jefferson St., Franklin, Indiana 46131.
11. The Radiation Safety Officer for this license is Patrick J. Byrne, Ph.D., DABR, CHP, DABSNM.
12. Licensed material shall only be used by, or under the supervision of:
- A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.
- B. The following individuals are authorized users for the material and medical uses as indicated:

Authorized User (M.D.,D.O.,etc.)

Material and Use

Mark Allen, M.D.

10 CFR 35.100,10 CFR 35.200; 10 CFR 35.300 (limited to oral administration of sodium iodide I-131)

Mary Below, M.D.

10 CFR 35.100,10 CFR 35.200

James Blahunka, M.D.

10 CFR 35.100,10 CFR 35.200,10 CFR 35.300

James R. Bognanno, M.D.

10 CFR 35.100,10 CFR 35.200

Justin P. Chang, M.D.

10 CFR 35.100,10 CFR 35.200; 10 CFR 35.300 (limited to oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries)

Stefan Andrew Hoff, M.D.

10 CFR 35.100,10 CFR 35.200; 10 CFR 300 (limited to the oral administration of sodium iodide I-131)

Tarun R. Jindal, M.D.

10 CFR 35.100,10 CFR 35.200; 10 CFR 300 (limited to the oral administration of sodium iodide I-131)

Kenyon K. Kopecky, M.D.

10 CFR 35.100,10 CFR 35.200,10 CFR 35.300

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 13-14817-01

Docket or Reference No.:

030-08553

Amendment No. 34

Authorized User (M.D., D.O., etc.)Material and Use

David Kurlander, M.D.

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300

Michael L. Lutz, M.D.

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300

Ronald Mastouri, M.D.

10 CFR 35.200

Gregory A. Merchun, M.D.

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300

Thomas N. Murphy, M.D.

10 CFR 35.100, 10 CFR 35.200

Mark Joseph Paluszny, M.D.

10 CFR 35.100, 10 CFR 35.200

Orin W. Perkins, M.D.

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300

Richard L. Scales, M.D.

10 CFR 35.100, 10 CFR 35.200

Paul W. Sheets, M.D.

10 CFR 35.100, 10 CFR 35.200

Chandraban Singh, M.D.

10 CFR 31.11

Mark Allan Sparrow, M.D.

10 CFR 35.100, 10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)

Stephan M. Stockberger, Jr., M.D.

10 CFR 35.100, 10 CFR 35.200; 10 CFR 35.300 (limited to oral administration of sodium iodide I-131)

Michael L. Swack, M.D.

10 CFR 35.100, 10 CFR 35.200

Perry E. Wethington, M.D.

10 CFR 35.100, 10 CFR 35.200

13. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

- A. Application dated July 15, 2013 (ML13198A571)
B. Letter dated November 27, 2013 (ML13338A662)

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 13-14817-01

Docket or Reference No.:
030-08553

Amendment No. 34

- C. Letter dated March 26, 2014 (ML14085A195)
- D. Letter dated December 28, 2016 (ML17003A062)
- E. Letter dated November 1, 2019 (ML19319C716)
- F. Letter dated January 12, 2020 (ML20014E722)
- G. Letter dated July 21, 2020 (ML20205L424)

Date: September 15, 2022By: _____
Sara A. Forster
Region III